Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Pötter, R; Gnant, M; Kwasny, W; Tausch, C; Handl-Zeller, L; Pakisch, B; Taucher, S; Hammer, J; Luschin-Ebengreuth, G; Schmid, M; Sedlmayer, F; Stierer, M; Reiner, G; Kapp, K; Hofbauer, F; Rottenfusser, A; Pöstlberger, S; Haider, K; Draxler, W; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group.
Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer.
INT J RADIAT ONCOL BIOL PHYS. 2007; 68(2): 334-340.
Doi: 10.1016/j.ijrobp.2006.12.045
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Luschin-Ebengreuth Gero
- Study Group Members Med Uni Graz:
- Kapp Karin S.
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: In women with favorable early breast cancer treated by lumpectomy plus tamoxifen or anastrazole, it remains unclear whether whole breast radiotherapy is beneficial. METHODS AND MATERIAL: Between January 1996 and June 2004, the Austrian Breast and Colorectal Cancer Study Group (ABCSG) randomly assigned 869 women to receive breast radiotherapy +/- boost (n = 414) or not (n = 417) after breast-conserving surgery (ABCSG Study 8A). Favorable early breast cancer was specified as tumor size <3 cm, Grading 1 or 2, negative lymph nodes, positive estrogen and/or progesterone receptor status, and manageable by breast-conserving surgery. Breast radiotherapy was performed after lumpectomy with 2 tangential opposed breast fields with mean 50 Gy, plus boost in 71% of patients with mean 10 Gy, in a median of 6 weeks. The primary endpoint was local relapse-free survival; further endpoints were contralateral breast cancer, distant metastases, and disease-free and overall survival. The median follow-up was 53.8 months. RESULTS: The mean age was 66 years. Overall, there were 21 local relapses, with 2 relapses in the radiotherapy group (5-y rate 0.4%) vs. 19 in the no-radiotherapy group (5.1%), respectively (p = 0.0001, hazard ratio 10.2). Overall relapses occurred in 30 patients, with 7 events in the radiotherapy group (5-y rate 2.1%) vs. 23 events in the no-radiotherapy group (6.1%) (p = 0.002, hazard ratio 3.5). No significant differences were found for distant metastases and overall survival. CONCLUSION: Breast radiotherapy +/- boost in women with favorable early breast cancer after lumpectomy combined with tamoxifen/anastrazole leads to a significant reduction in local and overall relapse.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Antineoplastic Agents, Hormonal - therapeutic use
- Breast Neoplasms - drug therapy
- Female - drug therapy
- Humans - drug therapy
- Mastectomy, Segmental - drug therapy
- Middle Aged - drug therapy
- Neoplasm Recurrence, Local - drug therapy
- Nitriles - therapeutic use
- Prospective Studies - therapeutic use
- Radiotherapy Dosage - therapeutic use
- Survival Rate - therapeutic use
- Tamoxifen - therapeutic use
- Triazoles - therapeutic use
- Find related publications in this database (Keywords)
- breast irradiation
- women with favorable early breast cancer
- lumpectomy plus hormone therapy with/without irradiation